



NeuroScientific

BIOPHARMACEUTICALS

ASX:NSB

**ASX ANNOUNCEMENT
1 DECEMBER 2023**

Chief Executive Officer Resignation

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) ("NeuroScientific" or "the Company") wishes to advise the resignation of its CEO Stephen Carter. Stephen has notified the Board yesterday that he will be resigning from the role effective 31 December 2023.

Chairman Paul Rennie said, "I would like to thank Stephen for his identification of the significant commercial opportunity of EmtinB for ocular indications. Since joining NSB Stephen clearly demonstrated his extensive clinical development expertise, and I was very confident in Stephen's ability to progress Emtin B into the clinic."

During the month of December 2023 Stephen will oversee the preparation of the documents necessary to make the Investigational New Drug (IND) submission to the US Food and Drug Administration (FDA) in Q1CY2024. The Board would like to thank Stephen for his service to NSB and wish him well with his future plans.

Stephen Carter said, "I would like to thank the NSB Board for providing me with the opportunity to review the EmtinB data and its potential clinical applications. I think EmtinB has enormous potential in retinal neurodegeneration indications and I would like to thank the NSB Board and staff for their support during my tenure as CEO.

The Company will commence a domestic and international search for a new CEO who will be able to successfully take over from Stephen.

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Paul Rennie
Chairman
NeuroScientific Biopharmaceuticals
ir@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.